Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

Kenji Hashimoto

DOI: https://doi.org/10.1111/pcn.12902

2019-07-11

Psychiatry and Clinical Neurosciences

Abstract:<p>Major depressive disorder (MDD) is one of the most disabling psychiatric disorders. Approximately one‐third of the patients with MDD are treatment resistant to the current antidepressants. There is also a significant therapeutic time lag of weeks to months. Furthermore, depression in patients with bipolar disorder (BD) is typically poorly responsive to antidepressants. Therefore, there exists an unmet medical need for rapidly acting antidepressants with beneficial effects in treatment‐resistant patients with MDD or BD. Accumulating evidence suggests that the <i>N</i>‐methyl‐D‐aspartate receptor (NMDAR) antagonist ketamine produces rapid and sustained antidepressant effects in treatment‐resistant patients with MDD or BD. Ketamine is a racemic mixture comprising equal parts of (<i>R</i>)‐ketamine (or arketamine) and (<i>S</i>)‐ketamine (or esketamine). Because (<i>S</i>)‐ketamine has higher affinity for NMDAR than (<i>R</i>)‐ketamine, esketamine was developed as an antidepressant. On March 5, 2019, esketamine nasal spray has been approved by the US Food Drug Administration. However, preclinical data suggest that (<i>R</i>)‐ketamine exerts greater potency and longer‐lasting antidepressant effects than (<i>S</i>)‐ketamine in animal models of depression and that (<i>R</i>)‐ketamine has less detrimental side effects than (<i>R,S</i>)‐ketamine or (<i>S</i>)‐ketamine. In this article, the author reviews the historical overview of the antidepressant actions of enantiomers of ketamine and its major metabolites norketamine and hydroxynorketamine. Furthermore, the author discussed the other potential rapid‐acting antidepressant candidates [i.e., NMDAR antagonists and modulators, low‐voltage‐sensitive T‐type calcium channel inhibitor, potassium channel Kir4.1 inhibitor, negative modulators of γ‐aminobutyric acid, type A (GABA_A) receptors] to compare them with ketamine. Moreover, the molecular and cellular mechanisms of ketamine's antidepressant effects have been discussed.</p><p>This article is protected by copyright. All rights reserved.</p>

neurosciences,psychiatry,clinical neurology